SCHEMBL20155192

SCHEMBL20155192

N=C(N)NCC1CCCCCCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 4/20 0.50
CYP2D6 P10635 1/20 0.50
CA2 P00918 2/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP3 P08254 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
CA9 Q16790 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
F2 P00734 2/20 0.41
PLG P00747 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
ST14 Q9Y5Y6 1/20 0.41
ADH1B P00325 1/20 0.40
ADH1C P00326 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19359628 1.00 EPHX1 (0.50) EPHX1CYP2D6CA2CA12CA1
SCHEMBL4103322 1.00 EPHX1 (0.50) EPHX1CYP2D6CA2CA12CA1
Hydrochloric Acid SCHEMBL28129388 0.98 CYP2D6 (0.48) EPHX1CYP2D6CA2CA12CA1
SCHEMBL13327339 0.93
Bicarbonate SCHEMBL2897700 0.92 CYP2D6 (0.58) EPHX1CYP2D6CA2CA12CA1
SCHEMBL7886602 0.88
Sulfuric Acid SCHEMBL11565505 0.84 TDP1 (0.45) EPHX1CYP2D6CA2CA12CA1
SCHEMBL14868308 0.84 CYP2D6 (0.44) EPHX1CYP2D6CA2CA12CA1
Hydrochloric Acid SCHEMBL11688617 0.82 CYP2D6 (0.43) EPHX1CYP2D6CA2CA12CA1
Hydrochloric Acid SCHEMBL11688594 0.82 CYP2D6 (0.43) EPHX1CYP2D6CA2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10414770-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2019-09-17 US disclosed
US-20180134716-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414770-B2 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB EPHX1 2370/4885CYP2D6 4519/4885CA2 1868/4885
US-20180134716-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB EPHX1 2370/4885CYP2D6 4519/4885CA2 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.